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Bone morphogenetic proteins (BMPs) are critically involved
in early development and cell differentiation. In humans, dys-
function of the bone morphogenetic protein type II receptor
(BMPR-II) is associated with pulmonary arterial hypertension
(PAH) and neoplasia. The ability of Kaposi sarcoma-associated
herpesvirus (KSHV), the etiologic agent of Kaposi sarcoma and
primary effusion lymphoma, to down-regulate cell surface
receptor expression is well documented. Here we show that
KSHV infection reduces cell surface BMPR-II. We propose that
this occurs through the expression of the viral lytic gene, K5, a
ubiquitin E3 ligase. Ectopic expression of K5 leads to BMPR-II
ubiquitination and lysosomal degradation with a consequent
decrease in BMP signaling. The down-regulation by K5 is
dependent on both its RINGdomain and amembrane-proximal
lysine in the cytoplasmic domain of BMPR-II. We demonstrate
that expression of BMPR-II protein is constitutively regulated
by lysosomal degradation in vascular cells and provide prelimi-
nary evidence for the involvement of the mammalian E3 ligase,
Itch, in the constitutive degradation of BMPR-II. Disruption of
BMP signaling may therefore play a role in the pathobiology of
diseases caused by KSHV infection, as well as KSHV-associated
tumorigenesis and vascular disease.
Bone morphogenetic proteins are multifunctional cytokines
regulating growth and differentiation (1). BMPs,3 similar to
other members of the transforming growth factor- superfam-
ily, signal by ligating heterodimeric transmembrane serine-
threonine kinase receptors. Association of the constitutively
active type II receptor leads to activation of the type I receptor
and phosphorylation of signaling Smad proteins (1). One of the
main type II receptors for BMPs in vascular cells is BMPR-II.
Complete loss of BMPR-II in mice leads to fetal death prior
to gastrulation (2), whereas postnatal loss leads to failure of
vessel maturation (3). In humans and rodents, partial loss or
mutation in BMPR-II predisposes to severe pulmonary arte-
rial hypertension (PAH) (4–7). Viral infections, including
HIV and Kaposi sarcoma-associated herpesvirus (KSHV),
have been implicated as etiological agents in the develop-
ment of PAH (8), although the evidence for the involvement
of KSHV is controversial (9, 10). Nevertheless, KSHV is the
etiologic agent of Kaposi sarcoma and primary effusion lym-
phoma (11) and may contribute to the pathogenesis of the
plasmablast form of multicentric Castleman disease (12).
Severe PAH has also been reported as a complication of
Castleman disease (13).
KSHV preferentially infects endothelial cells. It is dysfunc-
tional endothelial cell growth that gives rise to both the plexi-
form lesion in PAH and the spindle cell in Kaposi sarcoma (14,
15). Interestingly, KSHV expresses a lytic gene, K5, which
unlike other lytic genes is expressed for a prolonged period of
time (16). K5 is amembrane-associatedRINGE3 viral ubiquitin
ligase (17). K5 is known to target a number of host cell receptors
for ubiquitination and degradation, including the immunore-
ceptorsMHCClass I, ICAM-1, and B7.3 (17–20) and the endo-
thelial cell receptors platelet-endothelial cell adhesion
molecule and vascular endothelial cadherin (21, 22). Because
down-regulation of BMPR-II is associatedwith the pathology of
PAH (23, 24) and also the development of some forms of neo-
plasia (25–27), we investigated the regulation of BMPR-II in
vitro in the context of KSHV infection and ectopic K5
expression.
Our findings demonstrate that KSHV infection down-regu-
lates cell surface BMPR-II. We propose that this is caused
through the action of K5. We show that K5 ubiquitinates a
membrane-proximal lysine residue in the cytoplasmic domain
of BMPR-II. K5-mediated ubiquitination of BMPR-II leads to
its lysosomal degradation. Importantly, through these studies
with K5, we found a previously unreported endogenous mech-
anism of BMPR-II regulation in mammalian cells: constitutive
lysosomal degradation of BMPR-II. This may be mediated
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partly by the E3 ligase, Itch, or atrophin-1-interacting protein 4
(AIP4).
EXPERIMENTAL PROCEDURES
Tissue Culture—HeLa cell lines were grown in DMEM
(Invitrogen), and BC3 cells and Sultan cells were grown in
RPMI 1640 (Invitrogen). All medium was supplemented with
10% fetal calf serum (FCS) (PAA Laboratories) and 100
units/ml penicillin, 100 g/ml streptomycin, and 0.25 g/ml
amphotericin B (Sigma-Aldrich). Cells were incubated at 37 °C
with 5% CO2. The K5 stable cell line was created by viral trans-
duction of aHeLa parent cell line with pMSCV-puro-FLAG-K5
and selected with puromycin (1 g/ml) (Sigma-Aldrich).
Human pulmonary artery endothelial cells and pulmonary
artery smooth muscle cells were purchased from Lonza Wok-
ingham. Cells were propagated according to the instructions
supplied. Human umbilical vein endothelial cells (HUVECs)
were isolated and maintained in Medium 199 (M199; Invitro-
gen) containing 20% fetal calf serum, 28 g/ml gentamycin, 2.5
g/ml amphotericin B, 1 ng/ml epidermal growth factor, and 1
g/ml hydrocortisone (Sigma-Aldrich) until confluent. Pri-
mary cultures were dissociated with trypsin/EDTA (Sigma-
Aldrich) and passaged into tissue culture multiwell plates
(Falcon; BD Biosciences). Seeding density yielded confluent
monolayers within 24 h. HUVECs were cultured in M199 as
above for 18–24 h before infection with rKSHV.219.
KSHV Production—rKSHV.219 was produced from the
latently infected Vero line, which expresses the red fluorescent
protein (RFP) from the KSHV lytic PAN promoter and the
green fluorescent protein (GFP) from the EF-1 promoter, with
the gene for puromycin resistance as a selectable marker.
Briefly, Vero cells were maintained in Eagle’s minimal essential
medium, 2.2 g/liter NaHCO3, 10% FCS, penicillin and strepto-
mycin, and 5 g/ml puromycin (all Sigma-Aldrich). Vero cells
were infected with BacK50 and treated with 1.25 mM sodium
butyrate (Sigma-Aldrich) to induce lytic replication. After 48 h,
supernatants were removed, centrifuged at 500 g for 15 min
to remove cell debris, and then ultracentrifuged at 15,000 rpm
for 4 h. The resultant pellet was resuspended overnight in
EBM2 medium (Lonza). Infectious units were quantified by
infection of 293 cells and quantification of GFP-positive cells.
Infection of HUVECs andHeLaCells with KSHV—KSHVwas
diluted to the appropriate concentration in EBM2 and then
added to the confluent monolayers at a multiplicity of infec-
tion of 1 (HeLa) or 10 (HUVEC) before centrifugation at
450  g for 30 min (uninfected samples were treated in an
identical manner, except that there was no addition of
rKSHV.219). HUVECs were then incubated for a further 90
min at 37 °C with 5% CO2 before the KSHV-containing
mediumwas removed and replacedwithM199/DMEM includ-
ing supplements as described above.
Stimulation of BC3 Cells—Viral replication in BC3 cells was
induced by treating 2  107 cells (1  106/ml) with 2 mM
sodium butyrate (Sigma-Aldrich) for 24 h.
Flow Cytometry and Cell Sorting—Cells were lifted from
plates/flasks with 0.1 mM EDTA in PBS, stained with primary
antibody, and incubated at 4 °C for 1 h. Cells were then washed
three times with FACS solution (3% FCS in PBS) and incubated
with secondary, fluorophore-labeled antibody for 1 h at 4 °C
and washed with FACS solution prior to being resuspended in
500 l of PBS for analysis. Analysis was carried out on a
FACSCalibur flow cytometer (BDBiosciences). Cell sortingwas
carried out on a MoFlo cell sorter (Beckman-Coulter). Anti-
bodies used are: rabbit anti-BMPR-II H-300 (Santa Cruz Bio-
technology); secondary antibody goat anti-rabbit IgG
allophycocyanin (R & D Systems); and allophycocyanin-con-
jugated mouse anti-ICAM-1 (CD54) (BD Biosciences).
Transient Transfection—Transfections were performed
using the Mirus Bio TransIT-HeLaMONSTER transfection
kit according to the manufacturer’s instructions. Transgene
expression was assayed 48 h after transfection. Plasmids used
are: pEGFP-N1-BMPR-II-3GFP-tagged, pcDNA3-5-
Myc-tagged BMPR-II, pcDNA3-5-Myc-tagged BMPR-II-
R899X, MSCV-1-puro-AU1-tagged K5, MSCV-1-puro-AU1-
tagged K5W/I, and MSCV-1-puro-AU1-tagged K3.
Short Interfering RNA Transfection—HeLa cells were plated
out in 6-well plates in DMEM (with 10% FCS, no antibiotics) to
be 50% confluent the next day. Human pulmonary artery endo-
thelial cells were plated into 60-mm culture dishes in complete
EGM2 to be 70% confluent after 48 h. DharmaFECT 1 transfec-
tion reagent was used as per the manufacturer’s instructions.
60 h after transfection, the cells were lysed in 1% Triton X-100
in TBS (Complete protease inhibitor (Roche Applied Science))
at 1 107cells/ml lysis buffer; incubated on ice for 30 min; and
then centrifuged at 13,500 rpm for 10 min. The supernatant
was then assayed by immunoblot. The sequence of the short
interfering RNAmolecule (siRNA) oligonucleotides purchased
from Dharmacon is: Itch/AIP4, 5-guugggaacugcugcauua-3.
Sequences of the SMARTpool duplex for BMPR2 are: sense,
5-gaaccuguguuauuagugauu-3, antisense, 5-pucacuaauaacac-
agguucuu-3; sense, 5-caacauugcccgcuuuauauu-3, antisense,
5-puauaaagcgggcaauguuguu-3; sense, 5-gaaaggauggcugaac-
uuauu-3, antisense, 5-puaaguucagccauccuuucuu-3; sense, 5-
cauguaugcucuuggacuauu-3, antisense 5-puaguccaagag-
cauacauguu-3.
Lentiviral Transduction—Packaging, envelope, and vector
plasmid, pDG268 His6-WT ubiquitin-GFP, were cotransfected
into 293T cells. Viral supernatants harvested at 48 and 72 h
were concentrated by ultracentrifugation. The high titer virus
was incubated with HeLa and HeLa-K5 cells for 1 h at 37 °C for
transduction.
Immunoprecipitation and Immunoblotting—Cells were
lysed in 1% Triton X-100 TBS with Roche Applied Science
Complete protease inhibitors for 30 min in ice. Lysates were
then centrifuged at 13,500 relative centrifugal force for 10 min
at 4 °C. For immunoblots, the supernatant was heated in SDS
sample buffer, separated by SDS-PAGE, transferred to PVDF
membranes (Millipore), and probed with primary and second-
ary antibody. Reactive bands were detected by AmershamTM
ECL (GE Healthcare). For immunoprecipitation, the superna-
tant was precleared with CL-4B-Sepharose and protein G.
Then the sample was immunoprecipitated with antibody and
protein G, eluted in SDS reducing sample buffer, and immuno-
blotted and then probed with primary and secondary antibod-
ies and developed using ECL reagent. Antibodies used are:
mouse anti-BMPR-II (BD Transduction Laboratories), mouse
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anti-ubiquitin P4D1 (Cell Signaling), mouse anti-His (Qiagen),
mouse anti-Myc 9B11 (Cell Signaling), rabbit anti-phospho-
Smad 1/5 (Cell Signaling), rabbit anti-phospho-Smad 2 (Cell
Signaling), mouse anti-Itch (BD Transduction Laboratories),
and mouse anti--tubulin (Sigma).
ImmunofluorescenceMicroscopy—HeLa cells were grown on
collagen coated glass coverslips and transfected 24 h later. 48 h
after transfection, the coverslips were washed with PBS and
fixed with 3.8% formaldehyde. Cells were permeabilized with
0.1% Triton X-100 and blocked with 10% fetal calf serum in
PBS. Finally, the coverslips were stained with primary and sec-
ondary antibodies before being mounted in glycerol/PBS solu-
tion DAPI (VECTASHIELD)). Cells were viewed and photo-
graphed using an ultraviolet confocal microscope (TCS Leica),
and images were captured using ImagePro Plus 4.1 software.
Antibodies used are: mouse anti-Myc clone 4A6 (Upstate Bio-
tech Millipore) and mouse anti-LAMP-1 (Dako).
Reverse Transcription-PCR and Quantitative PCR—RNA
was prepared using either theQiagenRNeasymini kit orTRIzol
(Invitrogen) and converted to cDNAusing SuperScript III first-
strand synthesis supermix (Invitrogen) as described in theman-
ufacturer’s instructions with PCR settings as follows: 44 °C for
90 min, 90 °C for 10 min, and then 0 °C for 5 min. A PCR reac-
tion was then performed usingGoTaq Flexi DNApolymerase
(Promega) according to the manufacturer’s instructions with
PCR conditions as follows: 94 °C for 2min and then 30 cycles of
94 °C for 30 s, 57 °C for 30 s, and 72 °C for 1 min followed by
72 °C for 10 min and 4 °C for 10 min. The products were then
run on a 1% agarose gel. Specific primers used are: K5 sense,
5-ggatccaccatggcgtccaaggacgtagaag-3, K5 antisense, 5-atgc-
ggccgctcaaccgttgttttttggatgattt-3, GAPDH sense, 5-tgccagcc-
ccagcgtcaaag-3, GAPDH antisense, 5-gcaggggggagccaaaag-
ggy-3, -actin, sense, 5-catcaccattggcaatgagc-3, and antisense,
5-cgatccacacggagtacttg-3. For quantitative PCR reactions, 45
ng of cDNA was used in a PCR reaction according to the man-
ufacturer’s instructions using the SYBR Green JumpstartTM-
TaqReadymixTM (Sigma-Aldrich) containing 200 nM of the rel-
evant sense and antisense primers and 10 nM fluorescein
(Invitrogen). Specific primers used are: BMPR2 sense, 5-caaa-
tctgtgagcccaacagtcaa-3, BMPR2 antisense, 5-gaggaagaataatc-
tggataaggaccaat-3. The QuantiTect primer for 2-micro-
globulin was purchased from Qiagen.
Competition Radiolabeled Ligand Binding Studies—Cells
were grown to confluence in 24-well plates, pre-equilibrated in
binding buffer (DMEM/0.5% BSA containing 25 mM HEPES)
for 60 min at 4 °C, and then incubated at 4 °C for 3 h with
binding buffer containing either 125I-BMP4 (6 pM or 0.22
ng/ml) in the absence or presence of unlabeled BMP4 (300
ng/ml) or 125I-TGF- (25 pM) in the presence of absence of
unlabeled TGF- (100 ng/ml). Cells were then washed three
timeswith ice-cold binding buffer and solubilized in lysis buffer
(20 mM HEPES, pH 7.4, containing 10% (v/v) glycerol, 1% (v/v)
Triton X-100 and 0.05% (w/v) BSA). Each point was deter-
mined in triplicate for each experiment. Lysates were trans-
ferred to polystyrene tubes, and radioactivity was measured
with a Packard  counter.
BMP4/6 and TGF- Stimulation—Cells plated into 6-well
plates were quiesced in DMEM supplemented with 0.1% FCS
overnight. Cells were stimulated by adding DMEM supple-
mented with 0.1% FCS plus 10 ng/ml BMP4, 10 ng/ml TGF-,
or 1 ng/ml TGF- for 60, 30, 15, and 0 min. At the end of
stimulation, themediumwas removed, and the cells were snap-
frozen at 20 °C in 350 l of lysis buffer (10% Tris-HCL, 20%
SDS, 20% glycerol and Complete protease inhibitors (Roche
Applied Science)). The lysates were sonicated and analyzed by
immunoblot.
Concanamycin/Lactacystin Treatment—Concanamycin A
was dissolved in 100% ethanol and used at a final concentration
of 50 nM for 24 h. Lactacystin was used at 10 M for up to 5 h
(both Sigma-Aldrich). After treatment, the cells were lysed for
immunoblotting.
BMPR-II Constructs, BMPR-II Tail Truncations—A forward
primer was designed to amplify 5-Myc-tagged BMPR-II from
the BamHI restriction enzyme cleavage site of pcDNA3-
5-Myc-tagged BMPR-II-R899X. Reverse primers introduced a
premature stop codon and a new XhoI cleavage site. Another
reverse primer introduced a point mutation at amino acid 180,
mutating the lysine to an arginine. The surrounding wild type
amino acid sequence from the start of the BMPR-II cytoplasmic
domain (amino acids 171) is YRMLTGDRKQGLHSMNMME.
After amplification, the products were subcloned into pCR4-
TOPO cloning vector. The inserts were then cloned back into
pcDNA3, to give pcDNA3-BMPR-II-Y172X, pcDNA3-BMPR-
II-S185X, and pcDNA3-BMPR-II-K180R/S185X. Site-directed
mutagenesis was performed on the full-length 5-Myc-tagged
BMPR-II to give pcDNA3-BMPR-II-K180R. Oligonucleotides
used are: forward primer for truncated constructs, 5-tcggatccgg-
ccagggatgactt-3, and reverse primers, BMPR-II-Y172X, 5-ctcga-
gttatccaaagcataag-3; BMPR-II-S185X, 5ctcgagttagtgaagaccttgtt-
tacgctctcctgt-3; BMPR-II-K180R/S185X, 5-ctcgagttagtgaagacct-
tgtctacgctctcctgt-3. The forward primer for BMPR-II K180R is
5-aatgttgaccggtgaccgtagacaaggtcttcacagtatg-3, and the reverse
primer is 5-catactgtgaagaccttgtctacggtcaccggtcaacatt-3.
Statistics—A Student’s t test was used for analysis of two
normally distributed variables. For non-parametric data, a
Kruskall-Wallis test was used with post hoc Dunn’s test with
significance accepted as p 0.05.
RESULTS
Induction of Lytic KSHV Genes Reduces BMPR-II Protein
Expression in BC3 Cells—First we studied the primary effusion
lymphoma cell line, BC3, which is naturally latently infected
with KSHV. Untreated BC3 cells express only a subset of latent
viral genes, but lytic gene expression can be induced by treat-
ment with sodium butyrate (28). Treatment of BC3 cells and
Sultan cells (a Burkitt lymphoma cell line that lacks KSHV
infection) with 2 mM sodium butyrate for 24 h substantially
reduced BMPR-II protein levels in BC3 cells, but not in control
Sultan cells (Fig. 1a). Next we assessed whether de novo KSHV
infection down-regulates BMPR-II in HeLa cells and in endo-
thelial cells. Primary cultured humanumbilical vein endothelial
cells (HUVECs) or HeLa cells were infected with KSHV and
cultured for 7 or 2 days, respectively. KSHV infection of both
HUVEC and HeLa cells also reduced BMPR-II protein levels
(Fig. 1a).
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The Viral Ubiquitin Ligase, K5, Is Induced by Lytic KSHV
Infection—We next sought to determine the mechanism by
which lytic KSHV down-regulates BMPR-II. K5 is a KSHV-
encoded lytic gene that remains expressed for a prolonged
period of time after infection (16). K5 ubiquitinates and down-
regulates a number of host immunoreceptors, including
ICAM-1 (19, 20). To determine whether K5 is functional in our
in vitro system, we measured the cell surface expression of
ICAM-1 in BC3 cells by flow cytometry, before and after the
lytic reactivation ofKSHVwith sodiumbutyrate.A reduction in
ICAM-1 staining in BC3 cells after treatment with sodium
butyrate is seen at 24 h. Infection of HeLa and HUVECS with a
KSHV virus engineered to express GFP upon infection allowed
gating on the infected cell population. Again, a reduction in cell
surface ICAM-1 expression is seen in both HeLa cells and
HUVECs following de novo infection (Fig. 1b). To investigate
whether this reduction in ICAM-1 could be due to K5 expres-
sion, we measured K5 mRNA levels in HeLa and HUVEC fol-
lowing their infection with KSHV and in BC-3 cells in which
lytic replication was induced. We observed a substantial
increase in the relative expression levels of K5 in all three cell
types after lytic infectionwithKSHV (Fig. 1c). Furthermore, the
expression of K5 in HUVECs was maintained for at least 7 days
after infection.
Ectopic Expression of K5 Reduces Cell Surface BMPR-II Expres-
sion—To determine whether BMPR-II is a novel target for K5,
HeLa cell lines stably expressing ectopic K5 or K3 (another E3
ubiquitin ligase expressed by KSHV, which shares 40% homol-
ogy with K5) were evaluated (HeLa-K5 and HeLa-K3) (29). Ini-
tially, we employed radioligand binding studies with 125I-
BMP4, the natural ligand for BMPR-II, and 125I-TGF1 as a
control. We observed a 50% reduction in cell surface 125I-
BMP4 binding in HeLa-K5 cells when compared with HeLa-K3
cells (Fig. 2a). 125I-TGF binding
was unaffected. These data sug-
gested that in the presence of K5,
there is a specific reduction in the
number of BMP4 binding sites at
the cell membrane. Furthermore, in
HeLa cells expressing an E3 ligase-
inactive formof K5, K5W- (contain-
ing a single mutation tryptophan
alanine 47 in theRINGdomain) (30)
specific cell surface binding was
increased above baseline levels (Fig.
2a). By flow cytometry, we con-
firmed a reduction in cell surface
BMPR-II in HeLa-K5 cells when
compared with HeLa cells. In addi-
tion, ICAM-1 expression was also
reduced, indicating that K5 was
active in HeLa-K5 cells (Fig. 2b).
This K5-dependent decrease in
BMPR-II levels was confirmed by
immunoblotting for BMPR-II. The
predicted 150-kDa doublet seen in
control cells was reduced in abun-
dance in HeLa-K5 cells (Fig. 2c).
Importantly, we confirmed that there was no difference in
BMPR-II mRNA transcript levels in HeLa-K5 cells when com-
pared with HeLa cells (Fig. 2c). To ensure that this effect of K5
was not restricted to clonal effects of K5-expressing stable cell
lines, we confirmed the reduction in BMPR-II protein expres-
sion in HeLa cells transiently transfected with K5 (Fig. 2d). We
provided further evidence that the effect of K5 on BMPR-II was
dependent on the RING domain of K5 using an additional
ligase-defective K5 construct (K5W/I), which harbors two
mutations in the K5 RING domain (tryptophan 47 and isoleu-
cine 17 to alanines). These mutations prevent recruitment of
the cognate cellular E2 (31), and K5W/I is therefore unable to
catalyze the transfer of ubiquitin to substrate. When K5W/I
was transiently expressed in HeLa cells, we observed a marked
increase in BMPR-II protein when compared with control
HeLa cells (Fig. 2d). This observation was consistent with the
increased 125I-BMP4 binding in HeLa cells expressing K5W,
where cell surface BMP4 binding is higher than in control HeLa
cells (Fig. 2a). Taken together, these findings suggested that
K5W/I is effectively “trapping” BMPR-II at the cell surface and
inhibiting endogenous degradation of BMPR-II, analogous to
the related K3 (W41A) mutant that associates with, but is
unable to ubiquitinate, MHC I molecules (16).
K5 Expression Inhibits BMP-mediated Signaling via Smad
1/5—To confirm the functional relevance of the decrease in
BMPR-II expression, we investigated the effect of K5 on
BMP signaling. Usually, activation of the type I BMP recep-
tor by the constitutively active BMPR-II leads to phosphor-
ylation of Smads 1, 5, and 8 (32). By immunoblotting, we
found that phosphorylation of Smad 1 was markedly reduced
in HeLa-K5 cells when compared with HeLa cells following
BMP4 stimulation (Fig. 2e). Furthermore, this effect was spe-
cific to the BMP signaling pathway as there was no difference
FIGURE 1. KSHV infection causes a reduction in BMPR-II protein. a, immunoblot for BMPR-II protein in BC3
cells and control Sultan cells before and after treatment with 2 mM sodium butyrate for 24 h. BMPR-II levels in
HeLa cells 2 days after KSHV infection and also in HUVECS 7 days after KSHV infection when compared with
uninfected control cells are shown. b, flow cytometry for cell surface ICAM-1, a known target of K5, in BC3 cells
after induction of lytic KSHV and in HeLa cells infected with KSHV after 2 days and in HUVECs 7 days after
infection. Controls in these experiments were uninduced BC3 cells and uninfected HeLa and HUVEC cells
stained with secondary antibody only. c, RT-PCR analysis for K5 mRNA from KSHV-infected HeLa cells when
comparedwithHeLa controls andBC3 cells before andafter inductionof lytic KSHV infectionwithbutyrate and
in control and KSHV-infected HUVECs. Control HeLa cells and stably transfected HeLa-K5 cells served as nega-
tive and positive controls for the PCR, respectively. Representative images of three experiments are shown.
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in the levels of phospho-Smad 2 following TGF- stimula-
tion (Fig. 2f). Interestingly, there was no difference in phos-
pho-Smad 1/5 levels following TGF- stimulation, suggest-
ing that there was no alteration in
the cell surface levels of TGF- type I
receptors mediating Smad 1/5 phos-
phorylation (e.g. ALK1 or ALK5) in
HeLa and HeLa-K5 cells.
K5 Ubiquitinates BMPR-II for Ly-
sosomal Degradation—We next in-
vestigated the fate of BMPR-II when
co-expressedwithK5.Weused con-
focal microscopy to visualize the
location of a GFP-tagged BMPR-II
expressed in both HeLa cells
and HeLa-K5 cells. GFP-tagged
BMPR-II was located mainly at the
cell surface inHeLa cells (Fig. 3a). In
contrast, in HeLa-K5 cells, GFP-
tagged BMPR-II was internalized to
discrete vesicles within the cyto-
plasm. These cytoplasmic locations
completely co-localized with the
lysosomal marker LAMP-1 (Fig.
3b). To confirm that K5 targets
BMPR-II to the lysosomal pathway
for degradation, we used pharmaco-
logical inhibitors to block either the
proteasomal or the lysosomal path-
way. When HeLa-K5 cells were
treatedwith the lysosomal inhibitor,
concanamycin A (a specific inhibi-
tor that blocks lysosomal acidifica-
tion through selective inhibition of
the V-type ATPase), there was a
striking reversal of the degradation
of BMPR-II (Fig. 3c). Lactacystin
inhibits the proteasomal pathway by
inhibiting the 20 S proteasome
directly. HeLa-K5 cells treated with
lactacystin showed no reversal of
the loss of BMPR-II despite clearly
increasing the level of cellular ubiq-
uitin (Fig. 3d). These data con-
firmed that K5 targets BMPR-II to
be degraded via the lysosomal path-
way and not the proteasome. Inter-
estingly, in control HeLa cells
treated with concanamycin A, there
was also an increase in BMPR-II
protein by Western blotting. This
observation suggests that BMPR-
II is constitutively turned over
through the lysosomal pathway by
endogenous E3 ligases (Fig. 3c). We
confirmed this observation in pri-
mary cultured human pulmonary
artery endothelial cells and pulmo-
nary artery smooth muscle cells (Fig. 3e).
We next sought to demonstrate whether BMPR-II was
indeed ubiquitinated in the presence of K5. A His6-ubiquitin
FIGURE 2. K5 specifically reduces BMPR-II, a process that is dependent on the RING domain of K5.
a, cell surface binding of radiolabeled BMP4 in HeLa cells stably expressing K5 (HeLa-K5) when compared
with control HeLa cells and HeLa cells stably expressing K3 (a homolog of K5) (HeLa-K3) and in HeLa cells
expressing amutated, non-functioning K5 (K5W). Radiolabeled TGF-1 binding is also shown. (*, p 0.01).
Error bars indicate S.E. b, flow cytometry for cell surface BMPR-II and ICAM-1 expression in HeLa and
HeLa-K5 cells. Controls were incubated with secondary antibody alone. Error bars indicate S.E. c, immu-
noblot for BMPR-II protein in HeLa and HeLa-K5 cells showing reduced BMPR-II protein in HeLa-K5 cells.
Graph shows similar levels of BMPR-II mRNA transcripts in both cell lines. d, immunoblot for BMPR-II
protein levels in control HeLa cells, stably expressing HeLa-K5 cells and HeLa cells transiently transfected
with K5 or a non-functioning RING mutant of K5 (K5W/I). e, immunoblot showing the level of Smad 1
phosphorylation (P-Smad 1/5) following BMP4 stimulation in HeLa and HeLa-K5 cells. f, immunoblot of the
TGF- downstream signaling molecule, phospho-Smad 2 (P-Smad 2), in HeLa and HeLa-K5 cells following
TGF-1 stimulation. Studies shown are representative of 3 independent experiments.
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construct was transduced into HeLa and HeLa-K5 cells, and
after treatment with concanamycin A, BMPR-II was immu-
noprecipitated and the associated His-tagged ubiquitinated
proteins were visualized by immunoblot analysis. A high
molecular weight smear compatible with ubiquitinated
BMPR-II was seen in the HeLa-K5 lane but not the HeLa lane
(Fig. 3f), confirming BMPR-II as a ubiquitination target for
K5.
K5 Ubiquitinates BMPR-II on
a Membrane-proximal Lysine—K5
targets MHC Class I by preferen-
tially ubiquitinating a membrane-
proximal lysine (19). We investi-
gated whether this was also the case
for BMPR-II. The amino acid
sequence of BMPR-II reveals that
there is a single lysine residue pres-
ent in the cytoplasmic membrane-
proximal region of BMPR-II at posi-
tion 180 (Fig. 4a). To determine the
critical site for ubiquitination of
BMPR-II, we created three trun-
catedBMPR-II constructs: one lack-
ing the entire intracellular domain
(Y172X), a second truncated at
amino acid 185 but retaining the
lysine at 180 (S185X), and a final
construct also truncated at amino
acid 185 but harboring a point
mutation at position 180, substitut-
ing the lysine for an arginine
(K180R/S185X) (Fig. 4a). When co-
expressed with K5, only the trunca-
tion with the lysine at position 180
(S185X) was degraded, an effect that
was reversed with the addition of
concanamycin A. K5 was unable to
degrade either of the other trun-
cated receptors, Y172X or K180R/
S185X, both of which lack the lysine
at position 180. K5W/I was unable
to degrade any of the truncated
receptors (Fig. 4b). Furthermore, we
demonstrate that K5 is unable to
degrade a full-length BMPR-II har-
boring the K180R point mutation
(Fig. 4c). This suggests that the tail
of BMPR-II is not necessary for the
action of K5. Taken together, these
observations suggest that K5 targets
the lysine in the membrane-proxi-
mal region of BMPR-II, a process
that is dependent on the RING
domain of K5. Confocal microscopy
demonstrated that all three trunca-
tions trafficked to the cell mem-
brane, but in the presence of K5,
only the truncated receptor with the
lysine remaining in position 180 could be internalized to the
cytoplasm in a similar manner to wild type BMPR-II (Fig. 4d).
The E3 Ligase, Itch, Contributes to Constitutive Degradation
of BMPR-II in Mammalian Cells—To identify the participants
in the endogenous, constitutive turnover of BMPR-II, we used
siRNAs to knock down known members of the NEDD4-like
family ofHECTE3 ligases (Nedd4,Nedd4-2, Smurf 1 and 2, Itch
(AIP4), WWP1 and -2 and NEDL 1 and 2) in HeLa cells as this
FIGURE 3.K5 causes redistribution of BMPR-II from the cell surface to a lysosomal compartment. a and b,
confocal microscopy showing the localization of GFP-tagged BMPR-II (green), the lysosomal marker, LAMP-1
(red), nuclear DAPI stain (blue), and merged images in HeLa (a) and HeLa-K5 (b) cells. c, immunoblot showing
BMPR-II protein levels before and after treatment of HeLa and HeLa-K5 cells with concanamycin A (lysosomal
inhibitor) (vehicle is ethanol) andgraphofBMPR-IImRNA transcript levels under the sameconditions. Error bars
indicate S.E. d, immunoblots for BMPR-II and endogenous ubiquitin levels in the presence and absence of
lactacystin (proteasomal inhibitor). e, immunoblots for BMPR-II protein in pulmonary arterial endothelial cells
(PAECs) and pulmonary arterial smooth muscle cells (PASMCs) before and after treatment with concanamycin
A. f, panel i, viral transduction of HeLa and HeLa-K5 cells with a His6-tagged ubiquitin (6xHis-Ub) followed by a
BMPR-II immunoprecipitation (IP) andHisWesternblot. f,panels iiand iii,Westernblots (WB) show thepresence
of endogenous BMPR-II in input lysates (panel ii) and also the presence of transduced His6 ubiquitin (panel iii).
Studies shown are representative of 3 independent experiments.
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ligase family is known to be involved in TGF-/BMP signaling
(33, 34).We observed a consistent increase in BMPR-II protein
after knockdown of Itch (AIP4) (Fig. 5a). This observation was
replicated in human pulmonary
artery endothelial cells (Fig. 5b).
DISCUSSION
The bone morphogenetic protein
type II receptor plays a major role in
early development, carcinogenesis,
and vascular disease, particularly
pulmonary arterial hypertension
(PAH). Our studies were initially
prompted by the observation that a
significant proportion of patients
with idiopathic PAH were reported
to have latent KSHV infection (8),
although this finding is controver-
sial (10, 35). In addition, mutations
in BMPR-II are the main cause of
familial PAH (4, 5, 36), and reduced
expression of BMPR-II protein is
found in idiopathic PAH (23) and
experimental models of PAH (24).
Thus the identification of mecha-
nisms regulating cell surface expres-
sion of BMPR-II is of major interest.
K5 is a viral E3 ubiquitin ligase
known to be expressed during, and
long after, the induction of KSHV
lytic replication. K5 targets a num-
ber of host cell receptors for ubiq-
uitination and degradation, includ-
ing the immunoreceptors MHC
Class I, Natural Killer-activating
ligands MHC Class I-related chains
A and B, and activation-induced
C-type lectin, ICAM-1, B7.2 (18–20,
37), and the endothelial cell recep-
tors platelet-endothelial cell adhe-
sion molecule and vascular endo-
thelial cadherin (21, 22). Our data
are the first to identify that KSHV
K5 targets a growth factor signaling
receptor pathway. In addition, we
confirmed directly that K5 overex-
pression leads to ubiquitination of
BMPR-II. K5 is an E3 ligase with a
characteristic cytosolic N-terminal
RING-CH domain, responsible for
ubiquitination of the target protein.
K5 preferentially targets the mem-
brane-proximal lysine for ubiquiti-
nation (38, 39). Using a series of
truncated BMPR-II constructs, we
first confirmed that the cytoplasmic
domain of BMPR-II was essential
for the action of K5. Themostmem-
brane-proximal lysine residue in the cytoplasmic domain of
BMPR-II lies at position 180, predicted to be 8 amino acids
from the cell membrane. Mutation of this lysine residue to an
FIGURE 4. K5 targets the membrane-proximal lysine of BMPR-II (Lys-180). a, a series of N-terminally Myc-
tagged BMPR-II constructs were made: full-length wild type BMPR-II, full-length BMPR-II in which the lysine at
position 180wasmutated to arginine, truncated (S185X) BMPR-II, truncated BMPR-II in which the lysine at 180
was mutated to arginine (K180R/S185X), and BMPR-II in which the entire intracellular domain was missing
(Y172X). TM, transmembrane.b, immunoblot forMycprotein inHeLa cells following transient transfectionwith
theMyc-taggedBMPR-II tail truncation constructs and either K5 or the K5 RINGmutant, K5W/I, before and after
concanamycin A (Concan A) treatment. c, immunoblot for Myc protein in HeLa and HeLa-K5 cells after trans-
fection with the full-length constructs, Myc-BMPR-II or Myc-K180R, with and without pretreatment with con-
canamycinA.d, confocal imagesweregeneratedafter staining forMyc inHeLaandHeLa-K5 cells after transient
transfection with the Myc-tagged BMPR-II tail truncated constructs (magnification60 oil immersion objec-
tive). In d, all blots and images are representative of 3 independent experiments.
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arginine prevented the degradation of BMPR-II protein and
prevented distribution of the mutated BMPR-II to the lyso-
some. In addition, we confirmed that this lysine residue was
essential for BMPR-II degradation in the context of the full-
length receptor. Thus we have identified that BMPR-II is sus-
ceptible to targeting by E3 ligases at this membrane-proximal
lysine. We studied the fate of BMPR-II in the presence of K5
and show that ubiquitinated BMPR-II is targeted to the lyso-
some for degradation. Degradation of BMPR-II could be res-
cued by inhibition of the lysosome by concanamycin A, but not
by the proteasomal inhibitor, lactacystin. Importantly, con-
canamycinA treatment ofHeLa cells and primary cultured pul-
monary vascular cells increased the protein expression of
BMPR-II even in the absence of K5. This suggested that the
expression of BMPR-II protein is constitutively regulated by the
lysosome and that an endogenousmammalian E3 ligasemay be
involved in this process.
KSHV encodes a panel of immunemodulatory proteins (39).
Down-regulation of immunoreceptors by K5 presumably con-
tributes to reduced immune surveillance of KSHV, and a reduc-
tion in endothelial junctional molecules may allow the virus to
pass easily between neighboring cells. Why then should KSHV
target BMPR-II? One possible explanation is that the degrada-
tion of BMPR-II in the infected endothelial cell contributes to
apoptosis resistance, helping to facilitate KSHV persistence
within the host. In support of this, mice with conditional abla-
tion of endothelial BMPR-II demonstrate increased pulmonary
endothelial proliferation. A propor-
tion of these mice develop PAH
(40). In addition, infected endothe-
lial cells resistant to apoptosis could
facilitate KSHV lytic infection and
increase titers.
A further possibility is that
BMPR-II is involved in regulation of
the host immune response. The
identification of BMPR-II as an
additional substrate for Itch adds
support to this hypothesis (41).
Although TGF- signaling has an
established role in the immune
response (42), the role of BMPs is
largely unexplored, although BMP4
and BMP2 are involved in thymic
homeostasis by regulating T cell lin-
eage commitment and differentia-
tion (43). Ablation of BMPR-II in
the pulmonary endothelium or
transgenic overexpression of a dom-
inant negative BMPR-II in vascular
smooth muscle predisposes mice to
pulmonary hypertension accompa-
nied by cellular inflammation (40,
45). Autoimmunity is common in
PAH patients, and immune mecha-
nisms for PAH pathobiology are
rapidly achieving prominence (46).
A previous study has demon-
strated that BMPR-II in association with Dullard (a phospha-
tase) is degraded via the proteasomal pathway (47). In that
study, an E3 ligase was implicated but never determined. Here
we show that in the presence of K5, BMPR-II is degraded by the
lysosomal pathway and not by the proteasome. The disparity in
results may be explained because we studied endogenous
BMPR-II degradation, whereas Satow et al. (47) used an over-
expression system to study BMPR-II, which may preferentially
activate the proteasome to degrade excess BMPR-II.
Importantly, in our studies, concanamycin A treatment of
HeLa cells and primary cultured pulmonary vascular cells
increased the abundance of BMPR-II in the absence of K5.
Moreover, inactive forms of K5 enhanced cell surface expres-
sion of BMPR-II. These data suggested that the expression of
BMPR-II protein is constitutively regulated by the lysosome
and that an endogenous mammalian E3 ligase may be involved
in this process. Severalmembers of theNEDD4 family ofHECT
E3 ligases are known to play a role in the regulation of the BMP
and TGF- pathways. Smurf 1 and 2 belong to the NEDD4
family and regulate Smad protein degradation (48), and
through an interaction with the inhibitory Smads, the TGF-
receptor complex (44). Through siRNA screening, we identi-
fied Itch as an endogenous mammalian HECT E3 ligase that is
involved in BMPR-II degradation. Knockdown of Itch consis-
tently led to increased expression of BMPR-II in HeLa cells and
pulmonary artery endothelial cells. It remains to be confirmed
that Itch actually ubiquitinates BMPR-II in the same way as K5
FIGURE 5. siRNA knockdown of Itch causes an increase in endogenous levels of BMPR-II. a, immunoblots
for BMPR-II protein and Itch, demonstrating the effect of BMPR-II or ITCH knockdown in HeLa cells, when
compared with control siRNA (siCON). b, similar experiments in pulmonary arterial endothelial cells. Graphs
show results of densitometry from n 3–4 independent experiments (*, p 0.05 and **, p 0.01). Error bars
indicate S.E.
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andwhether other ligases are involved in BMPR-II degradation.
Itch has been implicated in a number of important cellular pro-
cesses, including the regulation of autoimmunity, Th2 cell dif-
ferentiation, and activation of TGF- receptor signaling via
Smad 2 (41).
In summary, we show for the first time that the viral E3 ligase,
K5, regulates the BMP signaling pathway via ubiquitination and
lysosomal degradation of BMPR-II. Moreover, we identify a
constitutive lysosomal pathway regulating cell surface expres-
sion of BMPR-II and implicate the likely involvement of the
mammalian E3 ligase, Itch, in this process.
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